Form D · Other
Akoya Biosciences, Inc.
Menlo Park, CA · CIK 0001711933
Offering snapshot reported Oct 2, 2018 · SEC filing
- Reported sold
- $24.5M Offering amount: $25.5M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 26, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 2, 2018 | Initial | $24,500,000 | No comparison | 6 | SEC filing |
| Jul 14, 2017 | Initial | $9,000,000 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-322630
Source: Form D, filed Oct 2, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Rob Hart | Executive |
| Brian Mc Kelligon | Director, Executive |
| Garry Nolan | Director |
| Thomas Raffin | Director |
| Robert Shepler | Director |
| Matthew Winkler | Director |
Issuer details
Industry: Other (See others in industry)
Address:
1505 O'brien Drive, Suite A 1
Menlo Park, CA, 94025
Menlo Park, CA, 94025